Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a late-stage clinical trial.
A personalized approach to diagnosis and treatment is needed when viral hepatitis and fatty liver disease coexist.
More people who participated in a specialized program lost weight compared with those who received standard care.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Name change emphasizes the role of metabolic dysfunction in fatty liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.